重组人血管内皮抑制素联合培美曲塞对非小细胞肺癌患者血清肿瘤标志物及血管内皮生长因子、碱性成纤维细胞生长因子的影响  

Effects of recombinant human endostatin combined with pemetrexed on serum tumor markers,vascular endothelial growth factor and basic fibroblast growth factor in patients with non-small cell lung cancer

作　　者：管伟[1] 陈健 何俊明[1] 楼国梁[1] 项信青[1] 付印 胡江苇 Guan Wei;Chen Jian;He Junming;Lou Guoliang;Xiang Xinqing;Fu Yin;Hu Jiangwei(Department of Cardiothoracic Surgery,Yiwu Central Hospital,Yiwu 322000,Zhejiang Province,China)

机构地区：[1]义乌市中心医院心胸外科,浙江省322000

出　　处：《中国基层医药》2021年第2期165-169,共5页Chinese Journal of Primary Medicine and Pharmacy

基　　金：浙江省义乌市科技计划项目(2016ywkj125)。

摘　　要：目的探讨重组人血管内皮抑制素联合培美曲塞对非小细胞肺癌患者血清肿瘤标志物及血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)的影响。方法选取2016年6月至2018年6月义乌市中心医院确诊的非小细胞肺癌患者102例,采用随机数字表法分为对照组(n=51例)和观察组(n=51例),对照组在常规治疗基础上联合培美曲塞化疗,观察组在对照组治疗基础上联合重组人血管内皮抑制素化疗,两组均以3周为1个周期,治疗2个周期后,观察两组近期疗效及药物不良反应,同时分别于治疗前后检测两组血清肿瘤标志物,包括糖类癌抗原125(CA125)、癌胚抗原(CEA)和细胞角蛋白19片段(CYFERA21-1),并检测两组血清VEGF、bFGF水平变化情况。结果观察组治疗有效率为80.39%(41/51),高于对照组的58.82%(30/51),组间差异有统计学意义(χ^(2)=10.995,P<0.001);观察组治疗后血清CA125、CEA、CYFERA21-1水平分别为(236.92±20.85)U/L、(10.83±2.12)pg/L、(2.06±0.32)pg/L,均低于对照组的(303.86±27.51)U/L、(16.53±2.96)pg/L、(3.42±0.51)pg/L(t=11.307、9.128、13.172,均P<0.001)。观察组治疗后血清VEGF、bFGF水平分别为(112.52±19.38)μg/L、(12.95±1.87)pg/L,均低于对照组的(185.02±30.14)μg/L、(20.84±2.61)pg/L(t=11.797、14.328,均P<0.001);对照组药物不良反应总发生率为17.65%(9/51),观察组为13.73%(7/51),两组差异无统计学意义(χ^(2)=0.580,P=0.445)。结论采取重组人血管内皮抑制素联合培美曲塞化疗能降低非小细胞肺癌患者血清肿瘤标志物及VEGF、bFGF水平,可有效控制患者体内肿瘤细胞活性,用药安全、有效。Objective To investigate the effect of recombinant human endostatin combined with pemetrexed on serum tumor markers,vascular endothelial growth factor and basic fibroblast growth factor in patients with non-small cell lung cancer.Methods A total of 102 patients with non-small cell lung cancer who received treatment in Yiwu Central Hospital from June 2016 to June 2018 were included in this study.They were randomly assigned to undergo treatment with either recombinant human endostatin combined with pemetrexed(observation group,n=51)or pemetrexed(control group,n=51)based on conventional treatment.All patients were treated for two courses of 3-week treatment.Short-term efficacy and adverse drug reactions were compared between the control and observation groups.Before and after treatment,serum tumor markers including carbohydrate antigen 125,carcinoembryonic antigen and cytokeratin-19 fragment(CYFERA21-1)as well as serum levels of vascular endothelial growth factor and basic fibroblast growth factor were detected.Results Effective rate in the observation group was significantly higher than that in the control group[80.39%(41/51)vs.58.82%(30/51),χ^(2)=10.995,P<0.001].Serum levels of carbohydrate antigen 125,carcinoembryonic antigen and cytokeratin-19 fragment(CYFERA21-1)in the observation group were(236.92±20.85)U/L,(10.83±2.12)pg/L,(2.06±0.32)pg/L,respectively,which were significantly lower than(303.86±27.51)U/L,(16.53±2.96)pg/L,(3.42±0.51)pg/L in the control group,respectively(t=11.307,9.128,13.172,all P<0.001).Serum levels of vascular endothelial growth factor and basic fibroblast growth factor were(112.52±19.38)μg/L and(12.95±1.87)pg/L respectively in the observation group,which were significantly lower than(185.02±30.14)μg/L and(20.84±2.61)pg/L in the control group,respectively(t=11.797,14.328,both P<0.001).There was no significant difference in total incidence of adverse drug reactions between the control and observation groups[17.65%(9/51)vs.13.73%(7/51),χ^(2)=0.580,P=0.445].Conclusion Chemotherapy

关 键 词：癌 非小细胞肺 抗肿瘤联合化疗方案 血管内皮生长因子类 成纤维细胞生长因子 重组人血管内皮抑制素 培美曲塞 

分 类 号：R734.2[医药卫生—肿瘤]